Benjamin List

Benjamin List
Born	Benjamin List 1/11/1968
Birthplace	Frankfurt, West Germany
Nationality	German
Occupation	Chemist, academic
Employer	Max Planck Institute for Coal Research, University of Cologne
Known for	Development of asymmetric organocatalysis
Education	Free University of Berlin (Diplom); Goethe University Frankfurt (PhD)
Awards	Gottfried Wilhelm Leibniz Prize (2016), Nobel Prize in Chemistry (2021)
Website	https://www.kofo.mpg.de/en/research/homogeneous-catalysis

Benjamin List (born 11 January 1968) is a German chemist whose work on organocatalysis—using small organic molecules to accelerate chemical reactions—fundamentally reshaped the field of asymmetric synthesis. He is best known for demonstrating in 2000 that the amino acid proline could catalyze aldol reactions with high enantioselectivity, a discovery that established organocatalysis as a general and independent strategy for building complex molecules. Together with Scottish-born American chemist David MacMillan, List was awarded the 2021 Nobel Prize in Chemistry by the Royal Swedish Academy of Sciences "for the development of asymmetric organocatalysis," a method that gave chemists a precise and more environmentally friendly way to construct molecules.

List directs the Max Planck Institute for Coal Research (Max-Planck-Institut für Kohlenforschung) in Mülheim an der Ruhr, Germany, and holds a professorship of organic chemistry at the University of Cologne. His aunt is developmental biologist Christiane Nüsslein-Volhard, who won the Nobel Prize in Physiology or Medicine in 1995, making them one of a small number of close relatives to have each received a Nobel Prize.

Over more than two decades of independent research, List's group has continued expanding the scope and conceptual foundations of organocatalysis. Their contributions span confined Brønsted acid catalysis, asymmetric counteranion-directed catalysis, catalytic asymmetric fragmentation, enantioselective cyclopropanation, and the conversion of biomass-derived feedstocks into useful chemicals.

Early life

Benjamin List was born on 11 January 1968 in Frankfurt, then part of West Germany. He grew up in an intellectually stimulating environment shaped in part by the scientific achievements of those around him. His aunt, Christiane Nüsslein-Volhard, is a distinguished developmental biologist who received the Nobel Prize in Physiology or Medicine in 1995 for her discoveries concerning the genetic control of early embryonic development. While this family connection to science provided an early context for intellectual inquiry, List has spoken about charting his own course within the natural sciences and developing his own passion for chemistry as a discipline offering a singular way of understanding life and the material world.

In interviews, List has reflected on the meaning of scientific inquiry, including questions as fundamental as what science can reveal about the purpose of life, and has consistently stressed the importance of broad human diversity within the scientific community. His early fascination with chemistry naturally directed him toward Germany's leading universities.

Education

List earned his Diplom (the German equivalent of a master's degree) in chemistry from the Free University of Berlin. He then moved to Goethe University Frankfurt for doctoral research, working under organic chemist Johann Mulzer. List completed his PhD in 1997 with a thesis titled Synthese eines Vitamin B₁₂ Semicorrins (Synthesis of a Vitamin B₁₂ Semicorrin), which focused on the total synthesis of complex natural product fragments and provided him with a rigorous grounding in synthetic organic chemistry.

Following his doctorate, List moved to The Scripps Research Institute in La Jolla, California, for postdoctoral research under Richard Lerner and Carlos F. Barbas III, both leading figures in chemical biology and catalytic antibodies. It was during this postdoctoral period that List began investigating whether individual amino acids could function as catalysts independently of the larger enzyme structures in which they normally operate. Those investigations directly seeded the organocatalysis research that would define his independent career.

Research

Asymmetric organocatalysis: background and significance

Asymmetric synthesis is the branch of chemistry concerned with producing molecules in a specific three-dimensional shape. Many biologically active molecules—including most pharmaceuticals—exist as pairs of mirror-image structures called enantiomers, which can behave very differently in the body. Producing only the desired enantiomer efficiently and reliably is therefore one of the central challenges in modern chemistry.

Before List and MacMillan's early-2000s discoveries, asymmetric catalysis relied almost entirely on two approaches: transition metal complexes, often expensive and potentially toxic, and enzymes, which are large, complex proteins difficult to produce and modify. The idea that simple, small organic molecules could serve as a third class of asymmetric catalyst—without metals, without enzymes—was not considered a general principle and had not been systematically pursued. Organocatalysis, as this third approach came to be called, changed that understanding entirely.

The 2000 proline discovery

In 2000, early in his independent research career, List published the paper that would become the foundation of his Nobel Prize. Writing with his former Scripps supervisors Richard Lerner and Carlos Barbas III, he demonstrated that proline—a single, simple amino acid—could directly catalyze an aldol reaction, one of organic chemistry's most important carbon–carbon bond-forming reactions, with high enantioselectivity. Proline is cheap, commercially available, and environmentally benign. Its ability to drive the preferential formation of one enantiomer over the other, something previously thought to require metal catalysts or full enzyme machinery, was a conceptual breakthrough.

Around the same time, David MacMillan at the University of California, Berkeley, independently reported that small organic amines could catalyze Diels–Alder reactions enantioselectively. MacMillan coined the term "organocatalysis" to describe this approach. The two independent and parallel discoveries together established organocatalysis as a third general pillar of asymmetric synthesis, standing alongside metal catalysis and biocatalysis, and opened an entirely new area of chemical research. Their complementary contributions were jointly recognised by the 2021 Nobel Prize in Chemistry.

Mechanistic frameworks and catalyst development

After joining the Max Planck Institute for Coal Research in 2003, List's group systematically broadened the conceptual and practical foundations of organocatalysis. Building on the mechanistic insight behind proline catalysis—where the amino acid forms a reactive enamine intermediate with a carbonyl substrate—his team explored and codified a range of organocatalytic activation modes. These include enamine catalysis, iminium ion catalysis, and various Brønsted and Lewis acid-mediated pathways, each providing different tools for achieving enantioselective transformations.

One particularly influential line of work led to the development of confined Brønsted acid catalysts. These are strong chiral acids whose reactive sites are enclosed within a precisely shaped molecular cavity, allowing exceptional stereochemical control over reactions that occur within that confined space. Based on imidodiphosphorimidate (IDPi) and related frameworks, these catalysts enabled transformations previously considered extremely difficult or impossible to perform enantioselectively, including reactions of small, highly reactive intermediates that conventional catalysts could not control.

List also introduced asymmetric counteranion-directed catalysis (ACDC), a conceptually distinct strategy in which a chiral counteranion paired with a reactive cationic intermediate controls the stereochemical outcome of the reaction. This proved broadly applicable beyond traditional covalent activation modes and extended the reach of organocatalysis to new substrate classes and reaction types.

Recent research directions

Throughout the 2010s and into the 2020s, List's research group continued expanding the boundaries of what organocatalysis could achieve, with particular attention to activating substrate classes that had historically resisted selective functionalization and to addressing problems relevant to sustainable chemistry.

In October 2024, his group published work in Science on catalytic asymmetric fragmentation of cyclopropanes, addressing the longstanding challenge of performing stereoselective carbon–carbon bond cleavage in cycloalkanes—a fundamental and difficult problem in organic chemistry.

A 2025 publication in Science tackled the photohydrolysis of furans, exploring how light-driven catalytic reactions can convert biomass-derived furan compounds into useful chemical building blocks. This work connects organocatalysis to broader efforts to reduce the chemical industry's dependence on petroleum-based feedstocks by developing efficient routes from renewable biomass. The furan photohydrolysis work was highlighted by Chemical & Engineering News as a significant step toward practical biomass-based synthesis.

Also in 2025, a publication in Nature Communications described new bis-indole chiral architectures developed by List's team as scaffolds for asymmetric catalysis. These privileged chiral structures represent a new family of catalyst frameworks intended to enable a broader range of enantioselective transformations. A separate 2025 paper in Nature Catalysis reported an organocatalytic enantioselective cyclopropanation of olefins using diazoalkanes and asymmetric counteranion-directed catalysis, offering a metal-free alternative to established cyclopropanation methods that have long required transition metal complexes.

Practical impact

The practical consequences of organocatalysis have been substantial. Because small organic molecules are generally cheaper, more stable, and less toxic than many transition metal catalysts, organocatalytic methods spread rapidly through pharmaceutical research, agrochemical synthesis, and materials science following List and MacMillan's early publications. The absence of metal residues in organocatalytic reactions is particularly valuable in pharmaceutical manufacturing, where trace metal contamination in drug substances is tightly regulated. Organocatalytic reactions also frequently proceed under milder conditions and with simpler experimental setups than metal-catalysed alternatives, lowering the barriers to synthesising complex chiral molecules at scale. The Nobel Committee noted that organocatalysis is now used in the synthesis of a wide range of compounds, including pharmaceuticals and other fine chemicals, and that it contributes to making chemistry more sustainable.

Career

List began his independent research career at The Scripps Research Institute before returning to Germany. In 2003, he became a director at the Max Planck Institute for Coal Research (Max-Planck-Institut für Kohlenforschung) in Mülheim an der Ruhr, one of Germany's oldest chemical research institutions, founded in 1912. Despite its name's historical reference to coal chemistry, the institute has long had a broader focus on catalysis and organic synthesis; its previous affiliated Nobel laureates include Karl Ziegler and Gerhard Ertl. At the institute, List founded and leads the Department of Homogeneous Catalysis, where his research group has developed new organocatalytic methods and deepened mechanistic understanding of the field.

In addition to his directorship, List holds a professorship of organic chemistry at the University of Cologne. He has also contributed to Hokkaido University's Institute for Chemical Reaction Design and Discovery (ICReDD) in Japan